Related Experiment Video

Updated: May 29, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Anti-EGFR-targeting agents in recurrent or metastatic head and neck carcinoma: a meta-analysis

Fausto Petrelli1, Sandro Barni

  • 1Oncology Unit, Azienda Ospedaliera Treviglio-Caravaggio, Treviglio, Italy. faupe@libero.it

Head & Neck
|September 29, 2011
PubMed
Abstract

Insights

Adding anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to standard therapy significantly improves outcomes for patients with advanced head and neck cancer, enhancing survival and response rates.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Anti-epidermal growth factor receptor (EGFR) therapies demonstrate efficacy in treating head and neck carcinoma.
  • Advanced head and neck carcinoma presents a significant clinical challenge.

Purpose of the Study:

  • To assess the efficacy and safety of anti-EGFR therapies in advanced head and neck carcinoma.
  • To provide a meta-analysis of existing clinical trials.

Main Methods:

  • A meta-analysis of six randomized trials involving 2257 patients with recurrent/metastatic head and neck carcinoma.
  • Data analyzed included progression-free survival (PFS), overall survival (OS), response rate, and toxicity.

Main Results:

  • Anti-EGFR therapy significantly increased response rates (RR = 1.62) and progression-free survival (HR = 0.70).
  • Inclusion of monoclonal antibody trials showed a significant increase in overall survival (HR = 0.83).
  • Increased incidence of adverse events including diarrhea, rash, anorexia, and hypomagnesemia was noted.

Conclusions:

  • The addition of anti-EGFR monoclonal antibodies to standard therapy significantly improves OS, PFS, and response rates in recurrent/metastatic head and neck cancer.
  • Anti-EGFR therapy represents a valuable treatment option for advanced head and neck cancer.

More Related Videos

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Translationally-Relevant Tumor Resection Model for Murine Preclinical Models of Oral Squamous Cell Carcinoma07:59

Translationally-Relevant Tumor Resection Model for Murine Preclinical Models of Oral Squamous Cell Carcinoma

Published on: April 3, 2026

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...